Palmitoyl Dipeptide-5 Diaminohydroxybutyrate_Dosage, benefits & legal status
Also known as Palmitoyl Dipeptide-6 Diaminohydroxybutyrate, Palmitoyl Dipeptide-5 Diaminohydroxy Butyrate, palmitoyl dipeptide 5 diaminohydroxybutyrate
The other half of the pair, and the one with the name problem.
What is Palmitoyl Dipeptide-5 Diaminohydroxybutyrate?
Plain language first. The technical label stays, but it never stands alone.Overview
The partner peptide in a two-part firming ingredient, with an old name still in wide use.
A palmitoylated dipeptide carrying a diaminohydroxybutyrate group, formerly designated Palmitoyl Dipeptide-6 Diaminohydroxybutyrate, supplied only as half of a patented two-peptide complex.
What it's used for
A topical firming peptide used in anti-aging serums and creams, always alongside its partner peptide.
How does Palmitoyl Dipeptide-5 Diaminohydroxybutyrate work?
What it does in the body, and where.This peptide is always supplied with its partner, and the two are marketed as acting together on the dermal-epidermal junction, the folded seam that anchors the outer layer of skin to the layer below. The honest summary of the mechanism is that it is described rather than demonstrated for either molecule separately.
- 01The fatty tail is what gets it inThe 16-carbon palmitic acid chain is there to carry a small, charged peptide through the lipid barrier at the surface of skin. Without it, a molecule like this would sit on top and do nothing.
- 02The named targets belong to the pairLaminin V, collagens IV, VII and XVII, and integrin beta 4 are the proteins the supplier names, and they are genuinely the anchoring proteins of the junction. But the supplier attributes them to the combination, not to either peptide alone.
- 03Its individual role is not documentedIngredient guides describe this one as a cell-communicating ingredient and as the companion peptide, which are characterizations rather than findings. No published experiment separates what this molecule does from what its partner does.
- 04Why the name changedUnder the older INCI convention this molecule was Palmitoyl Dipeptide-6 Diaminohydroxybutyrate. A 2020 update moved it to Dipeptide-5. Nothing about the molecule changed. Supplier documents, retailer ingredient lists and formulation blogs written before the change, and plenty written after, still carry the old name.

What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Skin conditioning, the function the cosmetic ingredient inventory assigns itnone
- Boosting dermal-epidermal junction proteins, the claim the supplier makes for the pairnone
- Cell communication, a description applied to it by ingredient guides with no study namednone
The published record
0
Papers about Palmitoyl Dipeptide-5 Diaminohydroxybutyrate · this compound only
Searched: Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, Palmitoyl Dipeptide-6 Diaminohydroxybutyrate.
Left out: SYN-TACKS (the trade name of the two-peptide material, not of this molecule); Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine (the partner peptide it is supplied with, which has its own page); Dipeptide-5 (the core shared by both peptides' names); Dipeptide-6 (too general on its own, so the full former name is searched instead); 794590-34-4 (the CAS number, which does not appear in titles or abstracts); 2999669-30-4 (a CAS number from a distributor that does not match the supplier's own documents); 2999669-02-0 (the second distributor number, which also does not match); FGF receptor (a receptor family with a large literature of its own).
Europe PMC was searched on November 22, 2026 for these terms and returned nothing.
Counted from Europe PMC indexing, not read by a person.

At a glance
Four things to know about Palmitoyl Dipeptide-5 Diaminohydroxybutyrate
Evidence
Cosmetic
Category
Skin and cosmetic
Common vial
Varies
Half-life
Not measured, and not the right question
How much, and do you cycle it?
The range, and whether you take breaks.Set by the finished product, daily, as directed by the product. Not cycled Community practice
Used daily as part of a routine. Nothing about it suggests tolerance or a need for a break, and nothing has been studied that would show either way.
Not measured, and not the right questionNo figure
No half-life has been published. It is applied to the skin in a finished cosmetic rather than dosed into the bloodstream, so a circulating half-life would not describe anything useful. The relevant question for a lipidated topical peptide is how much penetrates and how long it persists in the tissue, and that has not been published for this one.
You can compare this against the whole library to see where it sits.
How is it given?
Dosing context and source notes.Supplied as a ready-made solution, so there is nothing to mix.
The supplier's own formulation guidelines give this peptide a use range of 0.1 to 1 percent within the trade material, and recommend the complete material at 1 percent of a skin care formula. Those are two different numbers: 1 percent of the material does not mean 1 percent of this peptide. No use level has ever been published for this peptide applied on its own, because it is not sold on its own.
How do you store it?
Before mixing, and after.Room temperature, out of light. Cap it tight after each use.
Palmitoyl Dipeptide-5 Diaminohydroxybutyrate ships as a cream, gel, or serum. Keep it at room temperature away from sun and heat unless the label says otherwise. Refrigerating an emulsion can split the texture. Watch for color, smell, or separation changes and stop using it if any appear.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- A known allergy to this ingredient or to others in the same product, remembering that it may be listed under its former name
- Broken, cracked, or actively irritated skin
- Reading a claim made for the two-peptide complex as a claim about this molecule
Stop and get help
- A rash that spreads beyond where you applied it
- Swelling of the face, lips, or eyelids, or any trouble breathing
- Burning that does not settle after rinsing it off
Common effects
- No adverse effects are reported for the isolated peptide, and no published testing has looked for them.
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Palmitoyl Dipeptide-5 Diaminohydroxybutyrate approved?
And where the numbers on this page come from.Not as a medicine. Palmitoyl Dipeptide-5 Diaminohydroxybutyrate is sold without a prescription as a cosmetic ingredient, which is a different thing from being approved as a drug.
- Approval statusCosmeticSold without a prescription as an ingredient in cosmetics, such as skincare and hair products. The FDA does not approve cosmetics before they are sold, and being easy to buy says nothing about whether it works.
- RouteOn the skin (topical)
- Checked21 November 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sourcesdsm-firmenich, SYN-TACKS formulation guidelinesdsm-firmenich, SYN-TACKS CB product pageFormulation supplier ingredient page recording the 2020 INCI renamingCosmetic ingredient aggregator entry, Palmitoyl Dipeptide-5 DiaminohydroxybutyrateDistributor listing for SYN-TACKS CB with conflicting CAS numbers
What has happened recently
We have not yet written a full regulatory note for this compound. The status above is current as of the date shown.
You can compare this against the whole library, or read how to check a seller.
What else is like Palmitoyl Dipeptide-5 Diaminohydroxybutyrate?
Others in Skin and cosmetic, side by side.If you're weighing Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, it's worth reading Palmitoyl Hexapeptide-12, Palmitoyl Hexapeptide-19 (BoNT-L Peptide), and Palmitoyl Tetrapeptide-10 in the same class.
The other half of the pair, and the one with the name problem.
- Dose
- Set by the finished product
- How often
- Daily, as directed by the product
Pal-VGVAPG, one of the two original palmitoyl peptides Sederma launched in 1992. Judged safe as used in cosmetics; the firming evidence is thin.
- Dose
- A few ppm in the finished product (up to 0.002%)
- How often
- Daily
A Botox-like cosmetic peptide whose published evidence is 15 volunteers and a supplier's own testing.
- Dose
- Set by the finished product
- How often
- Daily, as directed by the product
A fatty-tailed cosmetic tetrapeptide with a labeling problem worth understanding.
- Dose
- Set by the finished product
- How often
- Daily, as directed by the product
Guides for this compound
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- dsm-firmenich, SYN-TACKS formulation guidelines(2013)The supplier's own formulation guidelines, cited for this peptide's CAS number and use range as the supplier states them. It lists Palmitoyl Dipeptide-5 Diaminohydroxybutyrate at a use range of 0.1 to 1 percent with CAS 794590-34-4, alongside its partner peptide at 0.1 to 1 percent with CAS 883558-32-5, and recommends the complete material at 1 percent of a skin care formula.
- dsm-firmenich, SYN-TACKS CB product page(2026)The supplier's current product page, read at source, confirming that the current active INCI name for this molecule is Palmitoyl Dipeptide-5 Diaminohydroxybutyrate and that it is supplied as one of a specific, patented combination of two highly active synthetic peptides.
- Formulation supplier ingredient page recording the 2020 INCI renaming(2026)The source of the renaming, read at source and cited for that one fact. A formulation supplier's ingredient page states plainly, as a 2020 INCI update, that Palmitoyl Dipeptide-6 Diaminohydroxybutyrate is now Palmitoyl Dipeptide-5 Diaminohydroxybutyrate. The same site's older pages still list the complex as containing Palmitoyl Dipeptide-6 Diaminohydroxy butyrate, and a companion page describes the complex as three peptides by splitting the long names in the wrong place, which is a useful illustration of how this naming confuses people in practice.
- Cosmetic ingredient aggregator entry, Palmitoyl Dipeptide-5 Diaminohydroxybutyrate(2026)An ingredient reference entry, read as a directory description of this peptide's individual role and labeled as such. It describes the molecule as a synthetic lipopeptide formed from the reaction of palmitic acid and diaminohydroxybutyric acid with dipeptide-5, and as a companion peptide to its partner that works as a cell-communicating ingredient supporting skin firmness and conditioning. No study is named for any of this, and the entry is an aggregator rather than a primary document.
- Distributor listing for SYN-TACKS CB with conflicting CAS numbers(2026)A distributor listing for the trade material, cited because its identifiers do not agree with the supplier's own documents. It gives the composition as Palmitoyl Dipeptide-5 Diaminobutyroyl Hydroxythreonine, Palmitoyl Dipeptide-5 Diaminohydroxybutyrate, glycerin and water, with CAS numbers 2999669-30-4, 2999669-02-0, 56-81-5 and 7732-18-5. The last two are glycerin and water. The first two do not match the 883558-32-5 and 794590-34-4 given in the supplier's own formulation guidelines, and the discrepancy was not resolved during this review.
